Home
ONCY
ONCY News

Latest Oncolytics Biotech Inc. (ONCY) News on November 6, 2025

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Business Wire

2 days ago

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

PR Newswire

9 days ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

PR Newswire

17 days ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

MT Newswires

2 months ago

Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

PR Newswire

2 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

MT Newswires

5 months ago

Oncolytics Appoints Jared Kelly as Chief Executive

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

CNW Group

5 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

MT Newswires

5 months ago

Oncolytics Outline New Clinical Trial Data in Poster Presentation at ASCO Meeting

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

CNW Group

5 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

6 months ago

Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

PR Newswire

6 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire

6 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

MT Newswires

6 months ago

Oncolytics to Present New Pancreatic Cancer Data at Oncology Meeting Next Month

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

PR Newswire

6 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

MT Newswires

7 months ago

Oncolytics Up 1.5% in U.S. Pre-market as Funds Pelareorep's Ongoing Clinical Development

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

CNW Group

7 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

PR Newswire

7 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

MT Newswires

8 months ago

RBC on Oncolytics's Phase 2 Breast Cancer Trial

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

GuruFocus.com

8 months ago

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

MT Newswires

8 months ago

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

PR Newswire

8 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

8 months ago

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire

8 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

CNW Group

9 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

MT Newswires

9 months ago

Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

PR Newswire

9 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

MT Newswires

9 months ago

Oncolytics Biotech Gets Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

PR Newswire

9 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

MT Newswires

9 months ago

Oncolytics Biotech CEO to Step Down Following Medical Leave of Absence

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

CNW Group

9 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

Simply Wall St.

9 months ago

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

9 months ago

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

MT Newswires

9 months ago

Oncolytics Biotech to Present New Efficacy and Safety Data at ASCO Symposium

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

CNW Group

9 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

Clinical Trials Arena

10 months ago

German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

MT Newswires

10 months ago

Oncolytics Biotech Says German Regulatory Approval Received for Full Patient Enrollment in Pancreatic Cancer Study

MT Newswires

10 months ago

Oncolytics Biotech Up 6.5% in U.S. Pre-Market as Germany Approves Continuing GOBLET Enrollment

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

PR Newswire

10 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Simply Wall St.

10 months ago

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

PR Newswire

10 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

MT Newswires

a year ago

Oncolytics Biotech to Present "Promising" Pelareorep Data at ASCO GI Symposium

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

PR Newswire

a year ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

MT Newswires

a year ago

Oncolytics Biotech Competes Safety Phase Enrollment for GOBLET Trial's Pancreatic Cancer Cohort

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

CNW Group

a year ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

a year ago

Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

MT Newswires

a year ago

Oncolytics Biotech Q3 Loss Narrows

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

PR Newswire

a year ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

PR Newswire

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

ONCY Stock Up on Regulatory Update From Breast Cancer Program

Zacks

a year ago

ONCY Stock Up on Regulatory Update From Breast Cancer Program

Oncolytics targets accelerated approval for oncolytic virus therapy

Pharmaceutical Technology

a year ago

Oncolytics targets accelerated approval for oncolytic virus therapy

MT Newswires

a year ago

Oncolytics Biotech Provides Clinical Updates

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

CNW Group

a year ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

MT Newswires

a year ago

Oncolytics Biotech Reports "Favorable" Results for BRACELET-1 Breast Cancer Study

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

PR Newswire

a year ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

PR Newswire

a year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

CNW Group

a year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Sernova Corp. Announces Appointment of New Chief Executive Officer

GlobeNewswire

a year ago

Sernova Corp. Announces Appointment of New Chief Executive Officer

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

PR Newswire

a year ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

MT Newswires

a year ago

Oncolytics Biotech Reports Q2 Loss of $7.5 Million

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

MT Newswires

a year ago

Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

CNW Group

a year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

MT Newswires

a year ago

Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence

MT Newswires

a year ago

Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

PR Newswire

a year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Oncolytics doses first subject in pancreatic cancer trial

Clinical Trials Arena

a year ago

Oncolytics doses first subject in pancreatic cancer trial

MT Newswires

a year ago

Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

PR Newswire

a year ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

a year ago

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

MT Newswires

a year ago

Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

CNW Group

a year ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire

a year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

MT Newswires

a year ago

Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

CNW Group

a year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript

MT Newswires

a year ago

Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

PR Newswire

a year ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

MT Newswires

a year ago

Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

CNW Group

a year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

PR Newswire

a year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

PR Newswire

a year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

CNW Group

a year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

CNW Group

2 years ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire

2 years ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

PR Newswire

2 years ago

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

PR Newswire

2 years ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

CNW Group

2 years ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

CNW Group

2 years ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

CNW Group

2 years ago

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Newsfile

2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

CNW Group

2 years ago

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

CNW Group

2 years ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

CNW Group

2 years ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

PR Newswire

2 years ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Simply Wall St.

2 years ago

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Newsfile

2 years ago

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Share on Social Networks: